IMMUNOPHENOTYPIC CHARACTERISTICS OF INFLAMMATORY BREAST CANCER
https://doi.org/10.17650/1994-4098-2009-0-3-4-15-19
Abstract
The investigation enrolled 31 patients with inflammatory breast cancer (IBC) treated at the N. N. Blokhin Cancer Research Center from 2006 to 2008. IBC is diagnosed on the basis of signs of rapid progression, such as localized or generalized breast induration, red- ness and edema. IBC accounts for less than 5% of all diagnosed breast cancers and is the most lethal form of primary breast cancer. We studied tumor markers of the immunophenotype of IBC and levels and subpopulations of immunocompetent tumor-infiltrating cells. We found that expression of HLA-DR is in negative correlation with MUC-1 expression and lymphoid cells tumor infiltration is asso- ciated with the increase in T-cell subpopulations.
About the Authors
A. I. Berishvili
N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
N. N. Tupitsyn
N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
K. P. Laktionov
N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Kleer C., van Golen K., Merajver S. Molecular biology of breast cancer metastasis: Inflammatory breast cancer: clinical syndrome and molecular deter- minants. Breast Cancer Res 2000;2(Suppl 6):423—9.
2. Chang S., Parker S.L., Pham T. et al. Inflammatory breast carcinoma inci- dence and survival: the surveillance, epi- demiology, and end results program of the National Cancer Institute, 1975— 1992. Cancer 1998;82:2366—72.
3. Hance K.W., Anderson W.F., Devesa S.S. et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966—75.
4. Cristofanilli M., Buzdar U., Hortoba’gyi G.N. Update on the man- agement of inflammatory breast cancer. The Oncologist 2003;8(2):141—8.
5. Nouri A.M., Torabi-Puor N., Oliver R.T. Isolation of human leucocyte antigen (HLA)-associated peptide(s)in absence of HLA-restricted specific cytolytic T lymphocytes (CTL). Eur J Cancer 2001;37(Suppl 6):110.
6. Тупицын Н.Н., Кадагидзе З.Г., Блохина Н.Г. и др. Экспрессия лейкоцитарных и родственных им антигенов на клетках рака молочной железы человека. Экспер онкол 1990;12(2):54—8.
7. Petrakou E., Murray A., Price M. Epitope mapping of antiMUC-1 Mucin protein core monoclonal antibodies. Tumor Biol 1998;19(Suppl 1):21—9.
8. Летягин В.П., Паниченко А.В., Крохина О.В. Иммуноморфологическое стадирование рака молочной железы. Вестн РОНЦ им. Н.Н. Блохина РАМН 2001;(3):44—7.
9. Kawashima I., Hudson S. J., Tsai V. et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998;59(1):1—14.
10. Nicolini A., Carpi A. Immune manipulation of advanced breast cancer: an interpretative model of the relation- ship between immune system and tumor cell biology. Med Res Rev 2009;29(Suppl 3):436—71.
11. Lin X., Wang X., Capek H.L. et al. Effect of invariant chain on major histo- compatibility complex class I molecule expression and stability on human breast
12. tumor cell lines. Cancer Immunol Immunother 2009;58(Suppl 5):729—36.
13. Conha A., Ruiz-Cabello F., Cabrera T. et al. Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast. Eur J Immunogenet 1995;22(4):299—310.
14. Тупицын Н.Н. Иммунофенотип рака молочной железы. В кн.: Рак молочной железы. Под ред.
15. Н.Е. Кушлинского, С.М. Портного, К.П. Лактионова. М.: РАМН, 2005. с. 174—97.
16. Schuetz F., Ehlert K., Schneeweiss A. et al. Treatment of advanced breast cancer with bone marrow-derived tumour- reactive memory T-cells: a pilot clinical study. Cancer Immunol Immunother 2009;59(Suppl 6):887—900.
17. Lucin K., Iternicka Z., Jonjic N. Prognostic significance of T-cell infil- trates, expression of beta 2-microglobulin and HLA-DR antigens in breast carcino- ma. Pathol Res Pract 1994;190(12):1134—40.
18. Артамонова Е.В., Огнерубов Н.А., Тупицын Н.Н., Летягин В.П. Рак молочной железы: иммунологические факторы прогноза. Воронеж: Воронеж. Гос. ун-т, 2005.
Review
For citations:
Berishvili A.I., Tupitsyn N.N., Laktionov K.P. IMMUNOPHENOTYPIC CHARACTERISTICS OF INFLAMMATORY BREAST CANCER. Tumors of female reproductive system. 2009;(3-4):15-19. (In Russ.) https://doi.org/10.17650/1994-4098-2009-0-3-4-15-19
Views:
917
Email this article 